Regulus Therapeutics

$0.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.002 (-0.38%) Today
+$0.02 (+3.77%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell RGLS and other stocks, options, and ETFs commission-free!

About RGLS

Regulus Therapeutics Inc. Common Stock, also called Regulus Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Read More Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA. The listed name for RGLS is Regulus Therapeutics Inc. Common Stock.

Employees
21
Headquarters
San Diego, California
Founded
Market Cap
19.29M
Price-Earnings Ratio
Dividend Yield
Average Volume
515.06K
High Today
$0.5466
Low Today
$0.5106
Open Price
$0.5274
Volume
188.61K
52 Week High
$1.74
52 Week Low
$0.4222

Collections

RGLS Earnings

-$1.15
-$0.77
-$0.38
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 12, After Hours

You May Also Like